Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Invion ( (AU:IVX) ) is now available.
Invion Limited has released a presentation to be used by its Executive Chair and CEO, Thian Chew, at investor meetings and seminars. The company is advancing its Photosoft™ technology, a next-generation Photodynamic Therapy (PDT) that offers a less invasive alternative to surgery for cancer treatment and has potential applications in combating antibiotic-resistant superbugs. This development positions Invion as a leader in innovative cancer and infectious disease treatments, potentially impacting its market presence and stakeholder interests.
More about Invion
Invion is a life-science company specializing in the research and development of Photosoft™ technology for treating cancers, atherosclerosis, and infectious diseases. The company holds exclusive licensing rights in various regions, including Australia, New Zealand, and parts of Asia and Oceania, and is listed on the ASX.
Average Trading Volume: 103,345
Technical Sentiment Signal: Sell
Current Market Cap: A$8.47M
For detailed information about IVX stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue